Saturday, December 03, 2022
name of Prensa Latina
Bandera inglesa
English Edition
name of Prensa Latina



Breakthroughs in oncological drugs revealed at Cuban congress

Breakthroughs in oncological drugs revealed at Cuban congress

Havana, Apr 29 (Prensa Latina) The Cuban drugs Savax and CIMAvax-EGF, now in clinical trials, have been added to the portfolio of pioneering Cuban products to treat cancer, which is the second major cause of death in Cuba.

The former, developed by the Center for Genetic Engineering and Biotechnology (CIGB), already passed Phase I of studies in humans for solid tumors in different locations some seven years ago with encouraging results, according to the director of business development and project management of the CIGB, Rolando Paez.

At present, he told Prensa Latina during the working sessions of the BioHabana 2022 International Congress that one percent of patients who received the drug are still alive, despite the fact that at that time some of them were in a terminal state and had no therapeutic treatment.

Now the second phase of clinical trials is being completed and a third phase is being prepared to use it in ovarian and other malignant tumors, he added.

This project was included as part of a contract with a CIGB joint venture in China, in order to further develop it in that market, while we look for new international partners, he added.

On the other hand, CIMAvax-EGF, designed to treat lung cancer, is being studied at the Roswell Park Institute in New York, in the United States.

According to statements made by Mary Reid, director of Collaborative Research and Associate Professor of Oncology, this scientific center is the only place in the United States that is currently using this vaccine for research purposes.


name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.